Lifecore Biomedical, Inc.

Lifecore Biomedical, Inc.

LFCRยทNASDAQ

$5.67

+1.5%
HealthcareDrug Manufacturers - Specialty & Generic

Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. It operates through Lifecore, Curation Foods, and Other segments. The Lifecore segment engages in the manufacture of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, including technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. This segment sells its non-HA products for medical use primarily in the ophthalmic, orthopedic, and other markets. The Curation Foods segment engages in processing, marketing, and selling of olive oils and wine vinegars under the O brand; and guacamole and avocado food products under the Yucatan and Cabo Fresh brands, as well as various private labels. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was incorporated in 1986 and is headquartered in Santa Maria, California.

At a Glance

Live Snapshot
Market Cap$212.68M
EPS-1.2700
P/E Ratio-4.46
Earnings Date07/31/2026

Intrinsic Alpha Methodology

Thesis Lenses

Signal ยท Driver ยท Risk

Signal

Medium confidence

Valuation multiple is compressed (P/E -4.5).

Valuation inputs: P/E -4.5, earnings yield N/A, momentum +1.5%.

If multiples stay elevated while momentum fades, downside repricing risk rises.

Driver

High confidence

Return profile is soft (ROE -29.0%, ROIC -8.1%).

Profitability stack: net margin -30.0%, ROE -29.0%, ROIC -8.1%.

Quality deterioration often appears in margins before it shows up in headline EPS.

Risk

High confidence

Downside profile is elevated and scenario stress-testing is essential.

Risk factors: liabilities/assets +99.4%, momentum +1.5%, net margin -30.0%.

Higher leverage with weak momentum and thin margins can amplify drawdown severity.

lfcr

Lifecore Biomedical, Inc. Market vs Earnings Trajectory

LFCR ยท NASDAQ

Loading price and EPS data...

Lifecore Biomedical, Inc.

Lifecore Biomedical, Inc. Fair Value Envelope

LFCR ยท NASDAQ

Our analysis suggests that LFCR has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $5.67, this represents a potential HIDDEN relative to our calculated worth for Lifecore Biomedical, Inc..

Intrinsic Value
Current Price: $5.67
3Y-68.0%
5Y-3.0%
10Y+195.0%
3Y+16.0%
5Y-78.0%
10Y-76.0%
3Y-67.0%
5Y+1.0%
10Y+233.0%
3Y-99.0%
5Y-99.0%
10Y-101.0%
3Y-74.0%
5Y-69.0%
10Y-29.0%
3Y-13.0%
5Y-56.0%
10Y-30.0%
Lifecore Biomedical, Inc.

Lifecore Biomedical, Inc. Profit Bridge

LFCR ยท NASDAQ
Revenue128.87M
Cost of Goods Sold (88.57M)
Gross Profit40.30M
Operating Expenses (57.54M)
Operating Income-17.25M
Interest Expense (21.84M)
Other Income/Expense-21.43M
Pretax Income-38.67M
Income Tax (43.00K)
Net Income-38.72M
Net Income
-38.72M

Profitability Analysis

Gross Margin

31.3%

Moderate margins typical of competitive industries. Monitor for pricing pressure or rising costs.

Operating Margin

-13.4%

Operating losses indicate the core business is unprofitable. Requires restructuring or revenue growth.

Net Profit Margin

-30.0%

Net losses indicate the company is burning cash. Sustainability depends on path to profitability.

Profitability Insight

Margin squeeze alert: Healthy gross margins but weak operating margins suggest excessive operating expenses. Cost optimization could unlock significant value.

31.27%
Gross Profit Margin
-4%
3Y-11.0%
5Y+146.0%
10Y+138.0%
-13.38%
Operating Profit Margin
94%
3Y+26.0%
5Y+852.0%
10Y+266.0%
-30.04%
Net Profit Margin
-421%
3Y-71.0%
5Y+364.0%
10Y+1296.0%
-2897.98%
Return on Equity
-2830%
3Y+2081.0%
5Y+17432.0%
10Y+52360.0%
-16.18%
Return on Assets
-442%
3Y-62.0%
5Y+129.0%
10Y+377.0%
-8.10%
Return on Invested Capital
105%
3Y+121.0%
5Y+516.0%
10Y+101.0%
LFCR

Lifecore Biomedical, Inc. Cash Conversion Engine

LFCR ยท NASDAQ
Net Income-38.72M
Depreciation & Amortization8.03M
Stock-Based Compensation10.16M
Change in Working Capital-4.70M
Others25.02M
Capital Expenditures-13.41M
Free Cash Flow-13.62M

Cash Flow Quality Analysis

FCF Conversion Rate

35.2%

Weak cash conversion. Significant portion of earnings not converting to cashโ€”review working capital trends and capital intensity.

CapEx Intensity

-6512.1%

Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.

FCF Growth Trend

+24.9%

Strong FCF growth demonstrates improving cash generation and business momentum. Positive signal for sustainability.

Working Capital Impact

-$4.70M

Moderate working capital outflow. Typical for growing businesses, but ensure it's supporting revenue growth, not inefficiency.

Cash Flow Quality Insight

Working capital strain: Significant cash tied up in operations. Monitor receivables collection, inventory turns, and payment terms to optimize cash conversion cycle.

lfcr

Lifecore Biomedical, Inc. Funding & Solvency Profile

LFCR ยท NASDAQ
Cash & Cash Equivalents20.80M
Net Receivables10.67M
Inventory28.16M
Other Current Assets18.02M
Total Current Assets78 M
Property, Plant & Equipment125.51M
Goodwill & Intangible Assets13.88M
Long-Term Investments0.00
Other Non-Current Assets8.47M
Total Non-Current Assets134 M
Total Assets
225.50M

Financial Health Analysis

Current Ratio

3.79x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

9.85x

High financial leverage. Heavy reliance on debt may indicate increased financial risk and potential solvency concerns.

Working Capital

57 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

34% Current

Capital-intensive business with significant long-term investments in property, equipment, or intangibles.

Financial Health Insight

Mixed signals: Strong short-term liquidity provides comfort, but high overall leverage requires careful monitoring of debt servicing capabilities and refinancing risk.

lfcr

Lifecore Biomedical, Inc. Street Expectations Map

LFCR ยท NASDAQ

Wall Street analysts project that LFCR stock may experience modest gains over the coming 12 months. The consensus 1-year price target stands at 6.00, with estimates ranging from a low of 6.00 to a high of 6.00.

Lowest Target
6.00
5.82%
Consensus Target
6.00
5.82%
Highest Target
6.00
5.82%

The consensus 1-year price target stands at 6.00, with estimates ranging from a low of 6.00 to a high of 6.00.

Analyst Consensus Analysis

Upside Potential

+5.8%

Moderate upside. Analysts expect positive returns but with limited margin of safety. Consider entry timing.

Analyst Agreement

0.0% spread

High analyst agreement. Narrow target range indicates strong consensus on valuation, suggesting clear investment thesis and predictable outlook.

Analyst Conviction

High

Positive outlook with reasonable agreement. Analysts generally optimistic about prospects with manageable uncertainty.

Market Sentiment Insight

Monitor and evaluate: Current analyst consensus suggests limited conviction or near-term catalysts. Stay informed on company developments and reassess positioning as new information emerges.

lfcr

Lifecore Biomedical, Inc. Insider Positioning

LFCR ยท NASDAQ

During the last 12 months, insiders have sold $985K worth of LFCR shares, with no buying activity reported.

3 Months

Bought

0

0.00

Sold

0

0.00

Net Activity

+0

+$0

3-6 Months

Bought

0

0.00

Sold

0

0.00

Net Activity

+0

+$0

6-9 Months

Bought

0

0.00

Sold

0

0.00

Net Activity

+0

+$0

9-12 Months

Bought

0

0.00

Sold

121.6K

985.03K

Net Activity

-985K

-$985K

Top Buyers

No buying activity

Top Sellers

1
JP

Josephs Paul

Director, Officer: Chief Executive Officer

54.9K sharesโ€ข1 transactions

$449K

2
LRD

Lake Ryan David

Officer: Chief Financial Officer

55.7K sharesโ€ข2 transactions

$445K

3
STD

Salus Thomas D.

Officer: Chief Legal & Administration

11.0K sharesโ€ข1 transactions

$90K

Insider Activity Analysis

Net Insider Sentiment

Bearish

Strong bearish signal with $985K net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.

Buy/Sell Ratio

0.00:1

Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.

Insider Participation

High Selling

3 insider sellers vs. 0 buyers. Widespread selling across multiple insiders may signal concerns.

0.00%
Dividend Yield
3Y-
5Y-
10Y-
ย 

lfcr Dividend History

LFCR
10Y CAGR +0%
Latest $0
Annual $0
Stable dividend payments
Last Period: +0%